BU is used in conditioning regimens before hemopoietic SCT. High BU exposure is associated with toxicity, whereas low BU exposure leads to higher rates of therapy failure. The pharmacokinetics of BU show large interpatient variability, hypothesized to be caused by variability in BU metabolism. In this report, the effect of genetic polymorphisms in three gluthatione S-transferase genes involved in BU metabolism (hGSTA1), GSTM1 (deletion-mutation) and GSTP1 (313A/G) on the pharmacokinetics of BU in Caucasian adult patients was investigated. In all, 66 adult patients received BU as part of their conditioning regimen. After the first infusion, two serum samples were collected and measured using a HPLC assay. A one-compartment population model was used to estimate individual pharmacokinetic parameters. The genetic variants of the three glutathione S-transferase (GST) genes were determined by pyrosequencing and PCR. A reduction of 14% in BU clearance was seen for the GSTA1*B allele and an increase in BU exposure was found. No relationship was found between polymorphisms in GSTM1 and GSTP1 and BU pharmacokinetics. This study shows that an increasing number of copies of GSTA1*B allele results in a significant decrease of BU clearance.
Introduction
BU is frequently used in high-dose conditioning regimens before hemopoietic SCT (HSCT) in malignant and nonmalignant diseases. BU has a narrow therapeutic index; high BU exposure is associated with toxicity, such as venoocclusive disease (VOD) and mucositis, 1 whereas low BU exposure leads to higher rates of graft failure and rejection. 2 Initially, BU was available as an oral formulation only, which resulted in high variability in exposure, probably as a result of inter-and intra-individual variation in bioavailability. However, the introduction of an i.v. formulation did not completely eliminate the variability in pharmacokinetics. 3 Therefore, treatment with BU in clinical practice is often individualized by therapeutic drug monitoring.
It is presumed that the variability in BU exposure could be assigned to BU metabolism. Conjugation with gluthatione is the primary route of metabolism of BU, catalyzed by isoenzymes of the glutathione S-transferase (GST) protein superfamily. GSTA1 is the predominant GST isoenzyme involved; GSTM1 and GSTP1 have 46 and 18% of the activity of GSTA1 in BU metabolism, respectively. 4 Therefore, it is hypothesized that singlenucleotide polymorphisms (SNPs) in the genes encoding for the isoenzymes of GST could influence BU clearance and that interindividual variability might be explained by SNPs in these genes.
Expression of GSTA1 is variable due to four SNPs in linkage disequilibrium in the promoter region of the gene; À631T or G, À567T, À69C, À52 G, designated as hGSTA1*A; and À631G, À567G, À69T, À52A, designated as hGSTA1*B.
5 GSTM1 is highly polymorphic; a deletion mutation resulted in no expression of the gene. 6 This is the case in B50% of the Caucasian population. 7 The SNP 313A/G in GSTP1 leading to amino acid replacement in the active binding site of GSTP1, decreases the catalytic activity of the enzyme. 8, 9 We hypothesize that SNPs in the genes encoding for the three GST isoenzymes influences the pharmacokinetics of BU. Furthermore, this effect may be dependent on race or age of the patients. We reported earlier on a study in which the effect of polymorphisms in the GSTs on BU pharmacokinetics in children was investigated. 10 No overall effect was found, however, a small effect was found in the older children suggesting an age effect on the expression of the GSTs. For this reason, we investigated the association between polymorphisms in genes encoding for the GSTs GSTA1, GSTM1 and GSTP1 and BU exposure in Caucasian adult patients undergoing HSCT. Patients receiving allogenic HSCT between 2004 and 2008 in the Leiden University Medical Center were included using the following selection criteria: age between 18 and 70 years, Caucasian ethnicity, receiving BU as conditioning before their allogenic HSCT with measured BU blood samples. Diagnoses that required HSCT were malignant; AML, CML, CLL, chronic myelomonocytic leukemia, non-Hodgkin's lymphoma or multiple myeloma or nonmalignant; aplastic anemia or sickle cell anemia.
Patients and methods

Patient and disease characteristic
Conditioning regimes and transplantation details
Patients received either myeloablative conditioning or nonmyeloablative conditioning. The myeloablative conditioning consisted of i.v. BU 0.8 mg/kg four times daily from day À9 to À6, i.v. alemtuzumab 15 mg once daily on days À6 and À5 and i.v. CY 60 mg/kg once daily on days À4 and À3. The non-myeloablative conditioning consisted of i.v. BU 0.8 mg/kg four times daily on days À6 and À5, oral fludarabine 50 mg/m 2 once daily from day À10 to À5 and anti-thymocyte globulin from day À4 to À1. Patients with chronic myelomonocytic leukemia received the same non-myeloablative conditioning plus 2 days of CY 750 mg/m 2 once daily on days À4 and À3. The graft was incubated with 20 mg of alemtuzumab just before infusion in all patients. BU dosing is based on actual body weight. All patients received 92 mg phenytoin three times daily for seizure prophylaxis, starting 1 day before BU administration.
Blood sampling
BU was administered i.v. in a 2 h infusion, starting in the morning at 0900 hours. Serum drug level measurements were carried out at 2.5 and 4.0 h after the start of the first infusion on the first day of treatment as part of routine patient care. Blood samples were stored at À20 1C before processing, when processing took place on the same day, the samples were stored at 4 1C.
A validated limited sampling model was used in order to minimize the number of blood samples necessary to calculate the BU clearance and area under curve (AUC).
11 BU was analyzed in serum by a validated HPLC 12 involving precolumn derivatization, liquid/liquid extraction, and UV detection according to Chow et al. 13 The assay was linear between 0.03 and 8 mg/L. The limit of quantification was 30 mg/L. Precision at 0.2 and 1.5 mg/L was 3.5 and 0.8%, respectively.
The pharmacokinetic model used was developed in MW/Pharm version 3.6 (Mediware, Groningen, The Netherlands).
14 A one-compartment population model with linear elimination was formulated, based on a BU model developed for children by this group first in NONMEM 11 and after that in MW Pharm. 15 Using the KinPop module of MW Pharm, in which an iterative twostage Bayesian procedure based on BU serum concentration values of 34 adult patients was carried out, the new means, medians and s.d. of the pharmacokinetic parameters were calculated. During the iterative two-stage Bayesian procedure, pharmacokinetic parameters were set to be distributed normally. The mean final pharmacokinetic parameters of the population pharmacokinetic model used are clearance: 13.3 L/h, volume of distribution: 50.8 L and BU half-life: 2.65 h.
The calculated mean population pharmacokinetic parameters, clearance and half-life, were individualized according to the maximum a posteriori Bayesian fitting method. 16 AUC was calculated by dividing the administered dose by clearance. No dose adjustments were made on the basis of the individual calculated AUC.
DNA extraction and GST analysis
Residual blood samples taken for routine patient care were used for genotyping. All blood samples were anonymized according to the instructions stated in the Codes for Proper Use and Proper Conduct (http://www. federa.org).
A crude DNA extract, prepared by lysing WBCs in SDS and proteinase k containing buffer, was used for PCR. The GSTA1 haplotype was determined by investigating the SNP at À69C/T. The following genetic variants for GSTP1 (313A/G, rs1695) and GSTM1 (deletion-mutation) were determined. 6 The SNPs in the GSTA1 and GSTP1 genes were separately genotyped by pyrosequencing 10 (Isogen, Maarssen, The Netherlands) and presence of the GSTM1 gene was determined by PCR amplification (215 bp) together with an internal control (albumin gene (350 bp). PCR products were analyzed on 2% agarose gels, as previously described by Zwaveling et al.
10
Clinical outcomes Next to pharmacokinetic parameters, the association of GST SNPs and HSCT clinical outcomes was assessed.
VOD was diagnosed according to the Seattle criteria: the occurrence of at least two of the following symptoms; painful hepatomegaly, unexplained weight gain of X2% from baseline and hyperbilirubinaemia; bilirubin 34 mmol/L or greater, present before day 21 after HSCT and after exclusion of other possible causes. 17 The diagnoses and severity of acute GVHD (aGVHD) was defined according to Glucksberg et al. 18 Rejection of the graft was defined as absence of donor cells. Engraftment was defined as stable donor chimerism.
Statistical analysis
All pharmacokinetic parameters are shown as mean ± s.d. Associations with BU pharmacokinetic parameters (clearance and AUC) and polymorphisms were tested with analysis of variance for GSTA1 and GSTP1 or Student's t-test for GSTM1. The effect of the number of copies of the T-allele in GSTA1 genotype was tested by linear regression analysis. The effect of the polymorphism on the defined clinical outcome was explored by w 2 -test. P-values o0.05 were considered significant. All statistical analyses were carried out in PASW statistics, version 17.0.01 (SPSS Inc., Chicago, IL, USA).
Results
Description of the cohort A total of 66 patients that received BU in the period between 2004 and 2008 were included. Baseline patient characteristics are shown in Table 1 . The average age of the patients was 52.1 years and 59% were male. Most of the patients (n ¼ 64) received BU in the non-myeloablative regime.
Patients included in this study received an average dose of 59.3 mg BU, which resulted in a mean BU clearance of 0.18±0.05 L/h Â kg and a mean AUC of 1153± 331 mmol Â min/L.
GST polymorphisms
The overall success rate of genotyping the GSTA1, GSTM1 and GSTP1 polymorphisms was 97, 98 and 88%,
respectively. An overview of genotype frequencies for all three SNPs is given in Table 2 . Missing GSTP1 genotypes were due to lack of patient material (n ¼ 8) and assay genotyping failure (n ¼ 2 for GSTA1 and n ¼ 1 for GSTM1). However, all variants showed Hardy-Weinberg equilibrium and were comparable with distributions of the genotypes found in other studies. 10, 19, 20 Effect of GST on BU pharmacokinetic parameters After the first dose of 0.8 mg/kg, a higher clearance was observed in the GSTA1 *A/*A genotype group (0.21 ± 0.055 L/h Â kg) compared with GSTA1*B heterozygous patients (0.18±0.041 L/h Â kg) and GSTA1*B homozygous patients (0.15 ± 0.039 L/h Â kg; Table 3 ). Analyzing using linear regression a reduction of 14% in BU clearance was found per GSTA1*B allele. The GSTA1 polymorphism could explain 18% of the variability in clearance.
An inverse effect was observed for the AUC, as shown in Figure 1 , AUC increases with 18% in GSTA1*B heterozygous patients and 35% for GSTA1*B homozygous patients. No significant differences in other parameters and GSTA1 genotypes were detected (Table 3) .
No relationship was found between the investigated polymorphisms in GSTM1 and GSTP1 and BU clearance. In GSTM1-positive individuals, a mean BU clearance of 0.18 ± 0.049 L/h Â kg was found, whereas in patients with a deletion mutation BU clearance was 0.19 ± 0.049 L/h Â kg.
BU clearance in patients with different GSTP1 genotypes were similar: 0.19±0.050 L/h Â kg for the AA genotype, 0.18 ± 0.041 L/h Â kg for the AG genotype and 0.21 ± 0.067 L/h Â kg for the GG genotype (P ¼ 0.162; Figure 2 ).
Effect of GSTA1 on clinical outcome VOD did not occur in any of the patients in this study and eight patients were diagnosed with mild aGVHD (grade one). In one patient engraftment did not occur and three patients experienced a secondary rejection of their transplant several months after transplantation. 
Abbreviations: ATG ¼ anti-thymocyte globulin; AL ¼ alemtuzumab; Flu ¼ fludarabine. a Presented underlying diseases in the category malignant diseases are AML (n ¼ 14), CML (n ¼ 3), CLL (n ¼ 6), non-Hodgkin lymphoma (n ¼ 12), multiple myeloma (n ¼ 21), chronic myelomonocytic leukaemia (n ¼ 2) and non-malignant diseases aplastic anaemia (n ¼ 7) and sickle-cell anemia (n ¼ 1). b Dosing schemes refer to Flu BU ATG ¼ BU 0.8 mg/kg four times daily on days À6 and À5, oral Flu 50 mg/m 2 once daily from day À10 to À5 and ATG from day À4 to À1. Flu BU ATG CY ¼ BU 0.8 mg/kg four times daily on days À6 and À5, oral Flu 50 mg/m 2 once daily from day À10 to À5, ATG from day À4 to À1 and CY 750 mg/m 2 once daily on days À4 and À3. BU AL CY ¼ BU 0.8 mg/kg four times daily from day À9 to À6, AL 15 mg once daily on days À6 and À5 and CY 60 mg/kg once daily on days À4 and À3. Abbreviation: HSCT ¼ hemopoietic SCT. GSTA1 genotype could not be determined in two patients (3%) and GSTM1genotype could not be determined in one patient (1.5%) because of assay failure. GTSP1 genotype could not be determined in eight patients (12%) because of the lack of material.
Of the HSCT patients with mild aGVHD, one patient was GSTA1*A/*A genotyped, five patients GSTA1*A/*B and two patients were GSTA1*B/*B (P ¼ 0.2). The three patients with rejection were GSTA1*B/*B genotyped (P ¼ 0.001), whereas the patient with non-engraftment was a GSTA1*B heterozygote. After a follow-up of 3 years 36 of 66 patients died, the OS was 45%. No effect of GSTA1 on OS was seen. Table 3 Effect of GSTA1 genotypes on BU pharmacokinetic parameters and HSCT patient parameters 
Discussion
In our adult Caucasian population, polymorphism in the GSTA1 gene resulted in a significantly lower BU clearance, hence a significantly higher exposure to BU. However, the effect of GSTA1 genotype on BU pharmacokinetics did not seem to influence BU toxicity in this study. However, all patients who experienced rejection were GSTA1*B homozygotes. In addition, no relation was found between polymorphisms in GSTM1 and GSTP1 genes and BU pharmacokinetic parameters. Therefore, interpatient variability in BU pharmacokinetics could be partly assigned to variances in the gene encoding the GSTA1 isoenzyme. BU shows large interpatient variability in clearance, which causes unpredictable exposure of BU resulting in either toxicity or therapy failure. It is hypothesized that differences in activity of the enzymes involved in BU metabolism (GSTA1, GSTM1 and GSTP1), caused by genetic polymorphisms, could explain the large interpatient variability.
This is the first study investigating the effect of polymorphisms in the genes encoding for these three GST isoenzymes on BU pharmacokinetics in Caucasian adults. The effect of polymorphisms in GSTA1 and GSTM1 on BU pharmacokinetics in adults has been studied before by Kusama et al., 21 Kim et al. 22 and Abassi et al. 19 The first two studies were carried out on Asian patients. In both studies no GSTA1*B homozygotes were observed. Kusuma et al. investigated the effect of the polymorphisms in 12 adult Japanese patients receiving BU orally and showed a reduction in clearance (Cl/F) of 40% in GSTA1*A/*B patients at steady state. Kim et al. showed a decrease in clearance of 12% after i.v. BU administration for GSTA1*A/*B patients. These results are in line with our results, though the reduction in clearance per GSTA1*B allele is somewhat less pronounced in comparison with the Japenese study in which BU is administered orally: 14% for GSTA1*A/*B genotype and 29% for GSTA1*B/*B genotype as measured after the first dose. Clearance after oral administration (CL/F) might be influenced differently by GST polymorphisms compared with clearance after i.v. administration, as BU is conjugated locally in the small intestine with glutathione and genetic variances could alter the first-pass effect. Furthermore, our patient population is Caucasian, which might result in a different effect of polymorphisms in the GSTs and BU pharmacokinetics than in Japanese patients.
Abassi et al. investigated the effect of genetic variances in GSTA1 and GSTM1 in a combined pediatric and adult population. No significant association between the genetic variances and BU IV clearance was found. Oral BU clearance was associated with the GSTA1 haplotype, but this was not considered clinically relevant.
In our previous study, 10 the effect of GSTA1 genotype on BU pharmacokinetic parameters in children was investigated; no significant effect of the polymorphism on BU clearance was detected. However, a small association of genetic variances in GSTA1 and BU clearance in older children was seen. This observation was the main reason for this study; to investigate the effect of the genetic variances in GSTs on BU clearance in adults.
We hypothesize that an overcapacity of the enzyme in children, which disappears when growing up, might result in a less pronounced effect of GSTA1 genotype on BU clearance in children. Therefore, we assume that the influence of polymorphisms in GSTA1 is dependent on age. In addition, this study nicely illustrates that the role of pharmacogenetics may differ in children as compared with adults.
Unfortunately Abassi et al. in their analysis did not differentiate between adult and pediatric patients, which compromise a direct comparison with the results of our study.
All three studies 19, 22, 21 also investigated the effect of GSTM1 genotype and found no association with the pharmacokinetics of BU. These findings are in line with our results. It is known that the contribution of GSTM1 and GSTP1 to BU metabolism is less then GSTA1, 46 and 18% of the activity of GSTA1, respectively.
The effect of the GSTP1 genotype on BU kinetics has not been studied before in adult patients. In our study, we did not see an effect of the investigated GSTP1 SNP on BU clearance; this is most probably due to the relatively small contribution of the GSTP1 enzymes to BU metabolism.
In our patients, the polymorphism in GSTA1 genotype could not be related to toxicity. However, we only observed mild toxicity, which impedes the finding of such a relationship.
In other studies higher incidences (20 to 41%) 23 of hepatic VOD were reported in patients undergoing HSCT and the incidence of hepatic VOD could be related to BU plasma levels. The absence of hepatic VOD in our study population could be explained by the non-myloablative conditioning given to our patients (64 out of 66), receiving BU only during 2 days, in contrast with the more toxic myeloblative setting in which an equal daily dose BU is given during 4 days. Another reason for low hepatic VOD incidence is the absence of CY in most of the conditioning regimes (62 of 66 patients). CY, and especially the combination with BU, is known for its hepatotoxicity.
Also the incidence of severity of aGVHD was low; eight patients were diagnosed with grade one aGVHD, which is indicated as clinically not relevant and is caused by the T-cell depletion of patient and graft during conditioning.
In three patients rejection of the transplant occurred, all three were GSTA1 homozygotes, according to our results leading to increase of BU exposure. This conflicts with earlier findings suggesting that rejection is related to low instead of high BU levels. 2 In our group, rejections took place late after transplantation, which is not compatible with direct BU toxicity. Furthermore, the rejections occurred in a group of 15 patients that were treated with rabbit anti-thymocyte globulin instead of horse antithymocyte globulin. Anti-thymocyte globulin has a long half-life and stays present for weeks to months after transplantation. Rejection is, therefore, much more likely to be caused by effects of the anti-thymocyte globulin on donor T-cells. Although the relationship between GSTA1 genotype and rejection is statistically significant, it is based on only three patients and no clear conclusion can be drawn.
In conclusion, this study demonstrates the effect of genetic variances in GSTA1 on BU clearance and exposure in Caucasian adult patients; resulting in a decrease in BU clearance in carriers of the GSTA1*B allele.
However, the clinical relevance of these findings is not clear, as in our study no clear effect of GSTA1 genotype on clinical outcome was observed. Ultimately, pharmacogenetics aims for prevention of aberrant drug response. We presume that the effect of polymorphisms in GSTA1 is probably relevant for the more toxic regimes only, since overall, a low incidence of toxicity and therapy failure was seen in our patient population. Nevertheless, we demonstrated that part of the interpatient variability in BU exposure can be explained by genetic variances in GSTA1 (18%).
BU therapy is often individualized by therapeutic drug monitoring. Eventually, the aim is to optimize individual therapy by determining the pharmacogenetic profile of the patient and predict pharmacokinetics of the drug before administering BU. Additional studies are needed to investigate the effect of GSTA1 genotype on BU pharmacokinetics and outcome in more toxic regimes and to optimize genotype-based dosing of BU.
